Disease Landscape and Forecast Insights

MARKET OUTLOOKThe treatment of Crohn’s disease (CD) includes not only conventional therapies, many of which are generically available, but also potent biologics, which are often reserved for…

MARKET OUTLOOK The moderate to severe Crohn’s disease (CD) therapy market presents an attractive commercial opportunity for new, effective treatments. Tumor necrosis factor-alpha (TNF-α)…

MARKET OUTLOOK The U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets include the predominantly entrenched TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s…

MARKET OUTLOOK Conventional agents (e.g., immunosuppressants, 5-ASAs) have long been used to treat pediatric Crohn’s disease (CD). Among the TNF-α inhibitors, Janssen/Merck’s Remicade and…

MARKET OUTLOOK The Crohn’s disease (CD) therapy market will continue to evolve over the next decade. The well-established tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., Janssen/Merck…

MARKET OUTLOOK U.S. gastroenterologists generally follow a step-up approach when treating Crohn’s disease patients that begins with safe, albeit often less-efficacious, therapies (e.g.,…

MARKET OUTLOOK There are multiple well-established therapies available to treat Crohn’s disease (CD). In particular, the mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen/…

Crohn’s disease (CD) is a chronic debilitating illness with limited effective treatment options, especially for patients with moderate to severe disease. Treatment options for CD include…

Although TNF-α inhibitors revolutionized the treatment landscape for moderate to severe Crohn’s disease (CD), considerable unmet need remains. For instance, a notable percentage of patients do…

Crohn’s disease (CD) and ulcerative colitis (UC) are chronic relapsing/remitting inflammatory diseases of the gastrointestinal tract that typically manifest symptoms including diarrhea, abdominal…

Last Updated 18 December 2015 Treatment options for Crohn’s disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis…

Crohn’s disease (CD) and ulcerative colitis (UC) are the two gastrointestinal inflammatory disorders that constitute inflammatory bowel disease (IBD), affecting approximately 1.25 million people…